

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph starting at page 30, line 12 with the following paragraph:

--In an embodiment, where rMal d 1 (2620) (database accession number: AJ488060) is the Bet v 1 scaffold protein, a protein variant comprises at least two primary mutations selected from the group consisting of: (E12V, E12I, E12M, E12L), P16A, (H40S, H40T), I43N, L44I, D47N, G65K, K70R, (E76H, E76R, E76K, ~~Q76H~~ E76Q), S107T, G108P, +109D, S110G, E129A, K152L, (P154S, P154T), P155S and optionally one or more secondary mutations are selected from the group consisting of: N28X, preferably N28T, K32X, preferably K32Q, E45S, E96X, +159X. In this context, as well as in the following examples, the first letter and number corresponds to the original amino acid code in a particular amino acid position. The following letter is the amino acid that can be substituted with the original amino acid. Parenthesis means that there are a number of different options when choosing to mutate in a given amino acid position. One of these can be chosen.--

Please replace the paragraph starting at page 31, line 5 with the following paragraph:

--In another specific embodiment, a protein variant of a Mal d 1 protein variant (rMal d 1 (2781)) comprises the sequence defined in SEQ ID NO 2:

GVYTYENEYITSEIPPPRLFKAFVLDADNLIPKIAPQAIKHAENIEGNGGPGTIKKITFGEGSQY
KYVKHRIDSVDHANYSYAYTLIEGDALTDTIEKVSYETKLVASGSGSIKKSISHYHTKGDVEI
MEEHVKAGKEKAHGLFKLIESYKDHDPDAYN,

said variant comprising the following primary mutations: I43N, L44I, D47N, G65K, K70R, ~~Q76H~~ E76Q. The rMal d 1 (2781) variant is an example of a protein variant according to the present invention that has increased Bet v 1 specific IgE reactivity in comparison with the “native” rMal d 1 2620. This is illustrated in detail in the Examples.--